At Biosysion, our leadership team in the field of early detection of cancers, critical diseases, and molecular diagnostics is comprised of passionate experts dedicated to pioneering advancements that save lives and improve healthcare outcomes. Get to know the individuals leading our efforts to revolutionize healthcare:
As the CEO of Biosysion, Amad S provides visionary leadership and strategic direction, guiding our mission to transform early detection and diagnosis in critical diseases. With a proven track record of success across healthcare and diversified sectors, Amad drives our commitment to pioneering solutions that empower both patients and healthcare providers.
<span style="font-size: 16px; caret-color: rgb(13, 13, 13); color: rgb(13, 13, 13); font-family: Söhne, ui-sans-serif, system-ui, -apple-system, " segoe="" ui",="" roboto,="" ubuntu,="" cantarell,="" "noto="" sans",="" sans-serif,="" "helvetica="" neue",="" arial,="" "apple="" color="" emoji",="" "segoe="" ui="" symbol",="" emoji";="" white-space:="" pre-wrap;"="">
Yan Zhang, our Chief Technology Officer.
With expertise in molecular biology, genomics, and diagnostic technologies, Yan spearheads the development of cutting-edge diagnostic tools and platforms that enable early detection and personalized treatment approaches for cancer and critical diseases.
Guiding our diagnostic strategy is Scott Johnson, our Chief Diagnostic Officer.
With extensive experience in clinical diagnostics and laboratory medicine, Scott oversees the development and validation of diagnostic assays and tests for early detection, prognostication, and monitoring of cancers and critical diseases.
Driving our scientific research and innovation is Andrew MacMahon, our Chief Scientific Officer.
With a background in biomedical research and molecular biology, Andrew leads our efforts to identify novel biomarkers, diagnostic targets, and therapeutic interventions for improving early detection and treatment outcomes in cancer and critical diseases.
Leading our clinical strategy and medical affairs is Mark Abramson, our Chief Medical Officer.
With expertise in oncology, pathology, and clinical research, Mark provides medical leadership and strategic guidance to ensure that our diagnostic solutions meet the highest standards of clinical utility, accuracy, and patient care.
Driving our commercial strategy and market expansion efforts is Harvey Johnson, our Chief Commercial Officer.
With a focus on customer engagement and market access, Harvey leads our efforts to commercialize and launch innovative diagnostic products and services that address unmet needs in early detection and molecular diagnostics.
Overseeing our informatics and digital health initiatives is Garry Miles, our Chief Information Officer.
With expertise in healthcare informatics and data analytics, Garry Miles leverages technology and data insights to optimize diagnostic workflows, enhance decision support, and improve patient outcomes in early detection and critical diseases.
Ensuring legal compliance and regulatory affairs is Sebastian Wahlstorm, our Chief Legal Officer.
With expertise in healthcare law and regulatory compliance, Sebastian provides strategic legal counsel and guidance to ensure that Biosysion's diagnostic solutions comply with all applicable laws, regulations, and quality standards.
Managing our financial strategy and operations is Muz Dungarwalla, Our Chief Financial Officer.
With a focus on financial stewardship and growth, Muz oversees financial planning, budgeting, and investment decisions to support Biosysion's mission of advancing early detection and molecular diagnostics in critical diseases.
At Biosysion, our leadership team in early detection, critical diseases, and molecular diagnostics is united by a shared commitment to innovation, excellence, and improving patient outcomes. Together, we are driving transformative advancements that have the potential to revolutionize healthcare and save lives.